MEDCO REPORTS PROFITABLE QUARTERMedco Research Inc. (ASE:MRE) of Los Angeles said net sales ofits cardiac arrhythmia treatment Adenocard in the UnitedStates by the company's North American licensee, FujisawaUSA Inc., were approximately $3.1 million. The increase insales was due, in part, to a large sales volume in December, thecompany said.

Second quarter ended Feb. 28.

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $803 116 +592Net income (loss) 124 (350) +135

QUEST LOSS DEEPENS FOR QUARTER

Quest BioTechnology Inc.(NASDAQ:QBIO) of Detroit said first-quarter results reflect the company's equity in the results ofoperations of AM Diagnostics Inc. for the period of Sept. 17,1990 through Sept. 30, resulting in an equity loss of $119,491.Quest acquired a 35.4 percent stake in AM Diagnostics on Sept.17, the company said. Quest's results for its fiscal year endingOct. 31 will reflect the company's equity on the results ofoperations of AM Diagnostics Inc. for the period of Sept. 17,1990, through June 30.

First quarter ended Jan. 31.

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $200 100 +100Operating income (loss) (78) (181) +57Net income (loss) (223) (188) -19Net income per share (loss) (.09) (.08) -13Outstanding shares 2,391 2,391 0

BIOGEN INCREASES REVENUES, EARNINGS

Biogen Inc. (NASDAQ:BGEN) of Cambridge, Mass., said product-based revenues grew more than 35 percent and accounted for78 percent of total revenues for the first quarter. Research anddevelopment expenses increased by nearly one-third, thecompany said, and amounted to 59 percent of revenues in thequarter compared with 57 percent in last year's first quarter.Jim Vincent, company chairman and chief executive officer,said, "Biogen continues to benefit from the substantial royaltiesfrom Intron AR alpha interferon and the expansion of thehepatitis B vaccination programs, which were recently given arecommendation for universal childhood immunization by afederal panel."

First quarter ended March 31.

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $18,065 14,143 +28Net income (loss) 2,875 1,737 +66Net income per share (loss) 0.05 0.01 +400Outstanding shares 27,110 22,607 +20

ABBOTT REPORTS INCREASED SALES, EARNINGS

Abbott Laboratories (NYSE:ABT) of Abbott Park, Ill., Chairmanand Chief Executive Officer Duane L. Burnham said thecompany's performance is a result of favorable product mix,good unit growth, productivity increases, new productintroductions and the favorable effect of the relatively weakerU.S. dollar.

Second quarter ended Feb. 28.

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $1,653,648 1,438,440 +15Operating income 371,106 328,024 +13Extraordinary income(1) 128,182 0 naNet income (loss) 254,170 224,950 +13Net income per share (loss) .59 .51 +16Outstanding shares 428,712 440,646 -3

(1) After-tax gain of the company's sale of its investment inAmgen Inc. in February.

BIOTECHNOLOGY DEVELOPMENT REPORTS PROFIT FOR YEAR

Biotechnology Development Corp. (NASDAQ:BIOD) of Newton,Mass., President and Chief Executive Officer Irwin J. Gruvermansaid: "In 1990, we completed the process of focusing all effortsin our equipment business, selling the AmpliMed subsidiary,which was performing pharmaceutical development work. OurMicrofluidics Corp. subsidiary shipped the largestmicrofluidizer system they have ever sold, on schedule andwith customer acceptance."

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,145 664 +72Operating income 71 60 +18Extraordinary income 128 0 --Net income (loss) 47 66 -29Net income per share (loss) .01 .02 -50Outstanding shares 3,050 3,024 neg.

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,329 $2,425 +37Operating income (loss) 86 (390) +122Extraordinary income 0 160 NANet income (loss) 337 (138) +344Net income per share (loss) .11 (.05) +320Outstanding shares 3,035 3,022 neg.

NEOZYME CUTS PER-SHARE LOSS

Neozyme Corp. (NASDAQ:NEOZ) of Cambridge, Mass., saidoperating expenses for the fourth quarter and year included$2.45 million paid to Genzyme Corp. under a technology licenseagreement for the transfer of technology conducted in sixdevelopment programs prior to October 1990. Neozyme Corp.was formed on Aug. 6, 1990, to fund research and developmentbegun by Genzyme on a select group of products that Genzymeidentified as significant new opportunities in its major businessareas.

Fourth quarter ended December 31, 1990

(Figures in thousands except per-share data.)

1990

Net income (loss) ($4,454)Net income per share (loss) (3.27)Outstanding shares 1,364

(c) 1997 American Health Consultants. All rights reserved.